Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10


Cediranib for metastatic alveolar soft part sarcoma.

Kummar S, Allen D, Monks A, Polley EC, Hose CD, Ivy SP, Turkbey IB, Lawrence S, Kinders RJ, Choyke P, Simon R, Steinberg SM, Doroshow JH, Helman L.

J Clin Oncol. 2013 Jun 20;31(18):2296-302. doi: 10.1200/JCO.2012.47.4288. Epub 2013 Apr 29.


Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma.

Saini V, Hose CD, Monks A, Nagashima K, Han B, Newton DL, Millione A, Shah J, Hollingshead MG, Hite KM, Burkett MW, Delosh RM, Silvers TE, Scudiero DA, Shoemaker RH.

PLoS One. 2012;7(8):e41401. doi: 10.1371/journal.pone.0041401. Epub 2012 Aug 3. Erratum in: PLoS One. 2012;7(11). doi:10.1371/annotation/8c74aaee-897d-4682-b62d-d95a3506c210.


Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts.

Monks A, Hose CD, Pezzoli P, Kondapaka S, Vansant G, Petersen KD, Sehested M, Monforte J, Shoemaker RH.

Anticancer Drugs. 2009 Sep;20(8):682-92. doi: 10.1097/CAD.0b013e32832e14e1.


The antitumor drug candidate 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole induces NF-kappaB activity in drug-sensitive MCF-7 cells.

Brantley E, Patel V, Stinson SF, Trapani V, Hose CD, Ciolino HP, Yeh GC, Gutkind JS, Sausville EA, Loaiza-Pérez AI.

Anticancer Drugs. 2005 Feb;16(2):137-43.


Fluorinated 2-(4-amino-3-methylphenyl)benzothiazoles induce CYP1A1 expression, become metabolized, and bind to macromolecules in sensitive human cancer cells.

Brantley E, Trapani V, Alley MC, Hose CD, Bradshaw TD, Stevens MF, Sausville EA, Stinson SF.

Drug Metab Dispos. 2004 Dec;32(12):1392-401. Epub 2004 Sep 8.


Increased expression of beta 2-microglobulin in multidrug-resistant tumour cells.

Scheffer GL, de Jong MC, Monks A, Flens MJ, Hose CD, Izquierdo MA, Shoemaker RH, Scheper RJ.

Br J Cancer. 2002 Jun 17;86(12):1943-50.


UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines.

Monks A, Harris ED, Vaigro-Wolff A, Hose CD, Connelly JW, Sausville EA.

Invest New Drugs. 2000 May;18(2):95-107.


The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network.

Webb CP, Hose CD, Koochekpour S, Jeffers M, Oskarsson M, Sausville E, Monks A, Vande Woude GF.

Cancer Res. 2000 Jan 15;60(2):342-9.


Interaction of the P-glycoprotein multidrug transporter (MDR1) with high affinity peptide chemosensitizers in isolated membranes, reconstituted systems, and intact cells.

Sharom FJ, Yu X, Lu P, Liu R, Chu JW, Szabó K, Müller M, Hose CD, Monks A, Váradi A, Seprôdi J, Sarkadi B.

Biochem Pharmacol. 1999 Aug 15;58(4):571-86.


Supplemental Content

Support Center